Skip to main content
. 2020 Nov 16;100(4):959–968. doi: 10.1007/s00277-020-04321-x

Table 2.

Pretreatment of HMAClax treated patients

Treatment line n Pretreatment
first line 8
second line 22

AZA

DAC

AZA + DLI

AZA + Lena

AZA + Lena +DLI

Lena

Sorafenib

DLI

10

3

2

2

2

1

1

1

fourth line 1 AZA, DAC + DLI
fifth line 1 DAC, ipilimumab, mitoxantrone, enasidenib

AZA 5 azacitidine, DAC decitabine, DLI donor lymphocyte infusion, Lena lenalidomide